Health-care companies rose after strong earnings from one fast-growing company.
Novo Nordisk shares rose after the Danish obesity-drug maker's first-quarter earnings topped Wall Street expectations. As widely anticipated, the drug maker reduced its growth forecast to reflect the appearance of copycat versions of its blockbuster weight-loss and diabetes drugs in the U.S.
Hims & Hers, the online pharmacy that recently struck a distribution deal with Novo Nordisk, saw shares rise.
If President Trump imposes drug tariffs that affect the cheap generic medicines Teva Pharmaceutical Industries makes, the company's chief executive says he'll have no choice but to raise their prices.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
May 07, 2025 17:32 ET (21:32 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。